Published Studies Related to Invega Sustenna (Paliperidone)
Well-designed clinical trials related to Invega Sustenna (Paliperidone)
Bilastine: in allergic rhinitis and urticaria. [2012]
A randomized, placebo- and active-controlled study of paliperidone
extended-release as maintenance treatment in patients with bipolar I disorder
after an acute manic or mixed episode. [2012]
Oral paliperidone: a review of its use in the management of schizoaffective disorder. [2011.06.01]
Paliperidone extended-release as adjunctive therapy to lithium or valproate in the treatment of acute mania: a randomized, placebo-controlled study. [2011.03]
Evaluation of the effect of paliperidone extended release and quetiapine on corrected QT intervals: a randomized, double-blind, placebo-controlled study. [2011.01]
A comparative study of paliperidone palmitate and risperidone long-acting
injectable therapy in schizophrenia. [2011]
Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers. [2010.10]
[Efficacy of paliperidone extended-release tablets in the improvement of social functions in schizophrenics: a randomized and controlled study]. [2010.08.03]
A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. [2010.07]
Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. [2010.07]
Efficacy and tolerability of paliperidone ER and other oral atypical antipsychotics in schizophrenia. [2010.06]
A randomized, placebo- and active-controlled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. [2010.05]
A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorder. [2010.05]
Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone. [2010.05]
Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia: meta-analysis of 3 randomized, controlled clinical trials. [2010.03]
Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. [2010.02]
Efficacy and safety of paliperidone extended-release in schizophrenia patients with prominent affective symptoms. [2010.01]
Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy
Chinese subjects. [2010]
A controlled, evidence-based trial of paliperidone palmitate, a long-acting
injectable antipsychotic, in schizophrenia. [2010]
A randomized, double-blind, placebo-controlled study of 2 dose ranges of
paliperidone extended-release in the treatment of subjects with schizoaffective
disorder. [2010]
A randomized, placebo-controlled study to assess the efficacy and safety of 3
doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. [2010]
Efficacy and safety of paliperidone palmitate in adult patients with acutely
symptomatic schizophrenia: a randomized, double-blind, placebo-controlled,
dose-response study. [2010]
Measuring social functioning with the personal and social performance scale in
patients with acute symptoms of schizophrenia: interpretation of results of a
pooled analysis of three Phase III trials of paliperidone extended-release
tablets. [2010]
Paliperidone extended-release tablets in patients with recently diagnosed
schizophrenia. [2010]
Intramuscular paliperidone palmitate. [2010]
Modeling the effectiveness of paliperidone ER and olanzapine in schizophrenia:
meta-analysis of 3 randomized, controlled clinical trials. [2010]
Paliperidone palmitate - review of the efficacy, safety and cost of a new
second-generation depot antipsychotic medication. [2010]
A comparison of serum prolactin concentrations after administration of
paliperidone extended-release and risperidone tablets in patients with
schizophrenia. [2010]
Efficacy and safety of paliperidone extended-release in schizophrenia patients
with prominent affective symptoms. [2010]
No pharmacokinetic interaction between paliperidone extended-release tablets and trimethoprim in healthy subjects. [2009.10]
Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. [2009.08.31]
Paliperidone extended-release for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. [2009.08]
The effects of paroxetine on the pharmacokinetics of paliperidone extended-release tablets. [2009.07]
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. [2009.06]
Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone. [2008.07]
Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. [2008.05]
Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. [2008.01]
Efficacy and Safety of Paliperidone Extended-Release Tablets: Results of a 6-Week, Randomized, Placebo-Controlled Study. [2007.12.15]
Paliperidone: a new extended-release oral atypical antipsychotic. [2007.10]
A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. [2007.09]
Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. [2007.07]
Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. [2007.02]
Treatment of schizophrenia with paliperidone extended-release tablets: A 6-week placebo-controlled trial. [2007.02]
Well-designed clinical trials possibly related to Invega Sustenna (Paliperidone)
Treatment response after relapse in a placebo-controlled maintenance trial in
schizophrenia. [2012]
Change in employment status over 52 weeks in patients with schizophrenia: an
observational study. [2011]
Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. [2010.12]
Relative bioavailability of two oral formulations of risperidone 2 mg: A single-dose, randomized-sequence, open-label, two-period crossover comparison in healthy Brazilian volunteers. [2010.11]
Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. [2010.11]
Relative bioavailability and pharmacokinetic comparison of two 2-mg risperidone tablet formulations: A single dose, randomized-sequence, double-blind, 2-way crossover study in healthy male volunteers in Thailand. [2010.09]
Association of 9-hydroxy risperidone concentrations with risk of switching or
discontinuation in the clinical antipsychotic trial of intervention
effectiveness-Alzheimer's disease trial. [2010]
Adjunctive use of atypical antipsychotics for treatment-resistant generalized
anxiety disorder. [2010]
The risk of death among adult participants in trials of antipsychotic drugs in
schizophrenia. [2010]
Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers. [2009.02]
Effect of rifampin, an inducer of CYP3A and P-glycoprotein, on the pharmacokinetics of risperidone. [2008.01]
Lack of bioequivalence between generic risperidone oral solution and originator risperidone tablets. [2007.05]
Other research related to Invega Sustenna (Paliperidone)
Paliperidone ER versus risperidone for neurocognitive function in patients with
schizophrenia: a randomized, open-label, controlled trial. [2012]
Paliperidone palmitate for schizophrenia. [2012]
Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics
and metabolism, clinical efficacy, safety and tolerability. [2012]
Different impacts of aquaporin 4 and MAOA allele variation among olanzapine,
risperidone, and paliperidone in schizophrenia. [2012]
Combination of citalopram plus paliperidone is better than citalopram alone in
the treatment of somatoform disorder: results of a 6-week randomized study. [2012]
Effect of paliperidone and risperidone on extracellular glutamate in the prefrontal cortex of rats exposed to prenatal immune activation or MK-801. [2011.08.18]
Paliperidone overdose with delayed onset of toxicity. [2011.07]
Prolongation of cardiac ventricular repolarization under paliperidone: how and how much? [2011.06]
Paliperidone extended-release: does it have a place in antipsychotic therapy? [2011.03.11]
Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysis. [2011.02.07]
Cardiac safety of the electroconvulsive therapy-paliperidone combination: a preliminary study. [2011.01]
A double-blind study of paliperidone palmitate and risperidone long-acting
injectable in adults with schizophrenia. [2011]
Evaluation of the effect of paliperidone extended release and quetiapine on
corrected QT intervals: a randomized, double-blind, placebo-controlled study. [2011]
Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. [2010.11]
Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania. [2010.10]
Serum concentrations of paliperidone versus risperidone and clinical effects. [2010.08]
Paliperidone extended release: a review of its use in the management of schizophrenia. [2010.07.09]
Hyperprolactinaemia during treatment with paliperidone. [2010.06]
Efficacy and safety of atypical antipsychotic drugs (quetiapine, risperidone, aripiprazole and paliperidone) compared with placebo or typical antipsychotic drugs for treating refractory schizophrenia: overview of systematic reviews. [2010.05]
Paliperidone use in the elderly. [2010.04]
Intramuscular paliperidone palmitate. [2010.03.01]
A comparison of continuous subcutaneous paliperidone infusion and repeated subcutaneous injection of risperidone free-base in rats. [2010.03]
Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets. [2010.02]
Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia. [2010.02]
Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. [2010.02]
[Non-fatal paliperidone overdose: a case report]. [2010.01]
Exploratory analysis of psychiatric-related utilization and costs associated with paliperidone ER compared with other oral atypical antipsychotics using pharmacy claims from an administrative database. [2010]
[Efficacy of paliperidone extended-release tablets in the improvement of social
functions in schizophrenics: a randomized and controlled study]. [Article in Chinese] [2010]
Paliperidone extended-release: a review of efficacy and tolerability in
schizophrenia, schizoaffective disorder and bipolar mania. [2010]
Tolerability of paliperidone: a meta-analysis of randomized, controlled trials. [2010]
Single- and multiple-dose pharmacokinetics and dose proportionality of the psychotropic agent paliperidone extended release. [2009.11]
The influence of hepatic impairment on the pharmacokinetics of paliperidone. [2009.10]
[Treatment with paliperidone extended-release tablets in a case of resistant undifferentiated schizophrenia: clinical improvement with 12 mg and evaluation through 3TRE scale] [2009.07]
Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER. [2009.07]
Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release. [2009.03]
Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. [2009]
Other possibly related research studies
Long-acting injectable risperidone and metabolic ratio: a possible index of clinical outcome in treatment-resistant schizophrenic patients. [2010.07]
Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. [2010.03]
Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. [2010.06]
[Successful quetiapine therapy in psychotic patients with mood elevation] [2009.12]
Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. [2009.12]
Effects of the antipsychotic risperidone on dopamine synthesis in human brain measured by positron emission tomography with L-[beta-11C]DOPA: a stabilizing effect for dopaminergic neurotransmission? [2009.10.28]
Paliperidon mediated modification of cortical inhibition. [2009]
Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. [2010.07]
Pharmacokinetics and efficacy of a direct switch from conventional depot to risperidone long-acting injection in Chinese patients with schizophrenic and schizoaffective disorders. [2009.08]
Effects of CYP2D6 and CYP3A5 genotypes on the plasma concentrations of risperidone and 9-hydroxyrisperidone in Korean schizophrenic patients. [2009.06]
|
